Molecular mechanisms of angiotensin II in the kidney: Emerging role in the progression of renal disease: Beyond haemodynamics

Nephrology Dialysis Transplantation

Volumn 13, Issue 5, 1998, Pages 1131-1142

  Wolf, Gunter ^a,b  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chronic renal failure; Compensatory hypertrophy; Macrophages monocytes; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; CYTOKINE; GROWTH FACTOR;

DISEASE COURSE; HEMODYNAMICS; HUMAN; IMMUNOMODULATION; KIDNEY DISEASE; KIDNEY FAILURE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANGIOTENSIN II; ANIMALS; CYTOKINES; DISEASE PROGRESSION; GROWTH SUBSTANCES; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY; KIDNEY DISEASES;

EID: 0031959599     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.5.1131     Document Type: Review

References (169)

1. Luft FC, Dietz R. Franz Volhard in historical perspective. Hypertension 1993; 22: 253-256
2. Volhard F. Der arterielle Hochdruck. Verh Dtsch Ges Inn Med 1923; 35: 134-184
3. Kronschwitz C. Franz Volhard. Leben und Werk. Sinemis Verlagsgesellschaft, Frankfurt am Main, 1997; 184-192
4. Goldblatt PJ. The Goldblatt experiment. A conceptual paradigm. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. Raven Press, New York, 1990; 21-32
5. Fasciolo JC. The experimental observation that led to discovery of angiotensin. Hypertension 1990; 16: 194-198
6. Page IH. Hypertension research. A memoir 1920-1960. Hypertension 1990; 16: 199-200
7. Tigerstedt R, Bergmann PG. Niere und Kreislauf. Scand Arch Physiol 1898; 8: 223-271
8. Skeggs LT. Discovery of the two angiotensin peptides and the angiotensin-converting enzyme. Hypertension 1993; 21: 259-260
9. Bumpus FM, Schwarz H, Page IH. Synthesis and pharmacology of the octapeptide angiotonin. Science 1957; 125: 886-887
10. Wolf G, Neilson EG. From converting enzyme inhibition to angiotensin II receptor blockade: new insight on angiotensin II receptor subtypes in the kidney. Exp Nephrol 1996; 4 [Suppl. 1]: 8-19
11. Bakhle YS. Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung. Nature 1968; 220: 919-921
12. Plas DI, Masucci FD, Sipos F, Denning GS. Specific competitive antagonists of the vascular action of angiotensin II. Circ Res 1971; 29: 664-672
13. Douglas JG. Angiotensin II receptor subtypes of the kidney cortex. Am J Physiol 1987; 253: F1-F7
14. Timmermanns PB, Carini DJ, Chiu AT et al. Angiotensin II receptor antagonists. From discovery to antihypertensive drugs. Hypertension 1991; 18 [Suppl. 3]: III136-III142
15. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351: 233-236
16. Sassaki K, Yamano Y, Badrhan S et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-I receptor. Nature 1991; 351: 230-233
17. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 1993; 268: 24539-24542
18. Laragh JH, Angers M, Kelly WG, Lieberman S. Hypotensive agents and presser substances. The effect of epinephrine, norepinephrine, angiotensin II and others on the secretory rate of aldosterone in man. JAMA 1960; 174: 234-240
19. Myers BD, Deen WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 1975; 37: 101-110
20. Blantz RC, Konnen KS, Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultraflltration coefficient of the rat. J Clin Invest 1978; 61: 910-921
21. Ausiello DA, Kreisberg JI, Roy C, Karnovsky MJ. Contraction of cultured rat glomerular cells of apparent mesangial origin after stimulation with angiotensin II and arginine vasopressin. J Clin Invest 1980; 65: 174-177
22. Sterzel RB, Rupprecht HD. Glomerular mesangial cells. In: Neilson EG, Couser WG, eds. Immunologic Renal Diseases. Lippincott-Raven, Philadelphia, 1997; 595-626
23. Harris PJ, Young JA. Dose-dependent stimulation and inhibition of proximal tubular sodium reabsorption by angiotensin II in the rat kidney. Pflügers Arch 1977; 367: 295-297
24. Schuster VL, Kokko JP, Jacobson HR. Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules. J Clin Invest 1984; 73: 507-515
25. Cogan MG. Angiotensin II: a powerful controller of sodium transport in the early proximal tubule. Hypertension 1990; 15: 451-458
26. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619
27. Anderson S, Rennke HG, Brenner BW. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000
28. Hannedouche T, Landais P, Goldfarb B et al. Randomised controlled trial of enalapril and β blockers in non-diabetic chronic renal failure. Br Med J 1994, 309: 833-837
29. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945
30. Ichikawa I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40: 583-596
31. Burns KD, Homma T, Harris RC. The intrarenal renin-angiotensin system. Semin Nephrol 1993; 13: 13-30
32. Taugner R, Hackenthal E, Helmchen U et al. The intrarenal renin angiotensin system. Klin Wochenschr 1982; 60: 1218-1222
33. Wolf G, Neilson EG. Angiotensin II as a renal cytokine. News Physiol Sci 1994; 9: 40-42
34. Wolf G, Ziyadeh FN. Renal tubular hypertrophy induced by angiotensin II. Semin Nephrol 1997; 17: 448-454
35. Seikaly MG, Arrant BS, Seney FD. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990; 86: 1352-1357
36. Czekalski S, Chansel D, Vandermeersch S, Ronco P, Ardaillou R. Evidence for angiotensin IV receptors in human collecting duct cells. Kidney Int 1996; 50: 1125-1131
37. Kohara K, Brosnihan KB, Chappell MC, Khosla MC, Ferrano CM. Angiotensin-(1-7). A member of circulating angiotensin peptides. Hypertension 1991; 17: 131-138
38. Wolf G, Mentzel S, Assmann KJM. Aminopeptidase A: a key enzyme in the intrarenal degradation of angiotensin II. Exp Nephrol 1997; 5: 364-369
39. Wolf G. Regulating factors of renal tubular hypertrophy. Clin Invest 1993; 71: 867-870
40. Wolf G. Angiotensin as a renal growth promoting factor. In: Mukhopadhyay SK, Raizada MK, eds. Tissue renin-angiotensin systems. Plenum Press, New York, 1995; 225-236
41. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989; 13: 305-314
42. Carmines PK, Fleming JT. Control of the renal microvasculature by vasoactive peptides. FASEB J 1990; 4: 3300-3309
43. Navar LG, Rosivall L. Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics. Kidney Int 1984; 25: 857-868
44. Zatz R. Haemodynamically mediated glomerular injury: the end of a 15-year-old controversy? Curr Opin Nephrol Hypertens 1996; 5: 468-475
45. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the reninangiotensin system? Kidney Int 1994; 45: 861-867
46. Neuwirth R, Satriano JA, DeCandido S, Clay K, Schlondorff D. Angiotensin II causes formation of platelet activating factor in cultured rat mesangial cells. Circ Res 1989; 64: 1224-1229
47. Katz AM. Angiotensin II: hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990; 22: 739-747
48. Norman JT, Badie-Dezfooly B, Nord EP et al. EGF-induced mitogenesis in proximal tubular cells: potentiation by angiotensin II. Am J Physiol 1987; 253: F299-F309
49. Norman JT. The role of angiotensin II in renal growth. Renal Physiol Biochem 1991; 14: 175-185
50. Wolf G, Neilson EG. Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 1990; 259: F768-F777
51. 1 receptor. Nephrol Dial Transplant 1993; 8: 128-133
52. Harris RC. Regulation of S6 kinase activity in renal proximal tubule. Am J Physiol 1992; 263: F127-F134
53. 1 receptor inhibits the effect of angiotensin II on DNA and protein synthesis of rat proximal tubular cells. Exp Nephrol 1997; 5: 253-262
54. Wolf G, Neilson EG. Angiotensin II as a hypertrophogenic cytokine for proximal tubular cells. Kidney Int 1993; 43 [Suppl. 39]: S100-S107
55. Wolf G, Killen PD, Neilson EG. Intracellular signaling of transcription and secretion of type IV collagen after angiotensin II-induced cellular hypertrophy in cultured proximal tubular cells. Mol Cell Biol 1991; 2: 219-227
56. 1ANG II-receptor. Am J Physiol 1995; 268: C925-C935
57. Wolf G, Kuncio GS, Sun MJ, Neilson EG. Expression of homeobox genes in a proximal tubular cell line derived from adult mice. Kidney Int 1991; 39: 1027-1033
58. Wolf G, Mueller E, Stahl RAK, Ziyadeh FN. Angiotensin Il-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 1993; 92: 1366-1372
59. Wolf G, Ziyadeh FN, Zahner G, Stahl RAK. Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene. Kidney Int 1995; 48: 1818-1827
60. Wolf G, Neilson EG. Effects of angiotensin II on proximal tubular cells stably transfected with the c-mas oncogene. Am J Physiol 1992; 263: F931-F938
61. Rosenberg ME, Hostetter TH, Kren S, Chmielewski D. Effect of angiotensin II and norepinephrine on early growth response genes in the rat kidney. Kidney Int 1993; 43: 601-609
62. Kip1. Kidney Int 1996; 50: 2112-2119
63. 1 cells. Nephrol Dial Transplant 1995; 10: 1305-1312
64. Wolf G, Ziyadeh FN, Helmchen U, Zahner G, Schroeder R, Stahl RAK. ANC II is a mitogen for a murine cell line isolated from medullary thick ascending limb of Henle's loop. Am J Physiol 1995; 26S: F940-F947
65. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 1992; 140: 95-107
66. Bakris GL, Re RN. Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol 1993; 264: F937-F942
67. Moriyama T, Fujibayashi M, Fujiwara Y et al. Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 1995; 6: 95-101
68. Wolthuis A, Boes A, Rodemann HP, Grond J. Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells. Kidney Int 1992; 41: 124-131
69. Orth SR, Weinreich T, Bönisch S, Weih M, Ritz E. Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells. Exp Nephrol 1995; 3: 23-33
70. Mattana J, Singhal PC. L-arginine supplementation antagonizes the effects of angiotensin II and endothelin I on mesangial cell proliferation. Cell Physiol Biochem 1995; 5: 176-192
71. 1 receptors. Kidney Int 1994; 45: 177-184
72. Gómez-Garre D, Ruiz-Ortega M, Ortego M et al. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996; 27: 885-892
73. Higueruelo S, Romero S. Angiotensin II requires PDGF-BB to induce DNA synthesis in rat mesangial cells cultured in an exogenous insulin-free medium. Nephrol Dial Transplant 1997; 12: 694-700
74. Anderson PW, Do YS, Hsueh WA. Angiotensin II causes mesangial cell hypertrophy. Hypertension 1993; 21: 29-35
75. Schulze-Lohoff E, Köhler M, Fees H, Reindl N, Sterzel RB. Divergent effects of arginine vasopressin and angiotensin II on proliferation and expression of the immediate early genes c-fos, c-jun and EGR-I in cultured rat glomerular mesangial cells. J Hypertens 1993; 11: 127-134
76. Huwiler A, Stabel S, Fabbro D, Pfeilschifter J. Platelet-derived growth factor and angiotensin II stimulate the mitogen-activated protein kinase cascade in renal mesangial cells: comparison of hypertrophic and hyperplastic agonists. Biochem J 1995; 305: 777-784
77. Johnson RJ, Alpers CE, Yoshimura A et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19: 464-474
78. Amann K, Nichols C, Törnig J et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996; 11: 1003-1011
79. Wolf G, Thaiss F, Schoeppe W, Stahl RAK. Angiotensin II-induced proliferation of cultured murine mesangial cells: inhibitory role of atrial natriuretic peptide. J Am Soc Nephrol 1992; 3: 1270-1278
80. Wolf G, Ziyadeh FN, Stahl RAK. Atrial natriuretic peptide stimulates the expression of transforming growth factor-β in cultured murine mesangial cells: relationship to suppression of proliferation. J Am Soc Nephrol 1995; 6: 224-233
81. Maric C, Aldfred GP, Antoine AM et al. Effects of angiotensin II on cultured rat renomedullary interstitial cells are mediated by ATIA receptors. Am J Physiol 1996; 271: F1020-F1028
82. Wolf G, Ziyadeh FN, Zahner G, Stahl RAK. Angiotensin II is mitogenic for cultured rat glomerular endothelial cells. Hypertension 1996; 27: 897-905
83. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49: 578-597
84. Matususaka T, Hymes J, Ichikawa I. Angiotensin in progressive renal diseases: theory and practice. J Am Soc Nephrol 1996; 7: 2025-2043
85. Hilgers KF, Mann JFE. Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. Kidney Blood Press Res 1996; 19: 254-262
86. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitors on glomerular lesions. Kidney Int 1991; 40: 195-202
87. Lane PH. Furosemide treatment, angiotensin II, and renal growth and development in the rat. Pediatric Res 1995; 37: 747-754
88. Tufro-McReddie A, Romano LM, Harris JM, Ferder L, Gomez RA. Angiotensin II regulates nephrogenesis and renal vascular development. Am J Physiol 1995; 269: F110-F115
89. Lumbers ER. Functions of the renin-angiotensin system during development, Clin Exp Pharm Physiol 1995; 22: 499-505
90. Fogo A, Yoshida Y, Yared A, Ichikawa I. Importance of angiogenic action of angiotensin II in the glomerular growth of maturing kidneys. Kidney Int 1990; 38: 1068-1074
91. Hilgers KF, Reddi V, Krege JH, Smithies O, Gomez RA. Aberrant renal vascular morphology and renin expression in mutant mice lacking angiotensin-converting enzyme. Hypertension 1997; 29: 216-221
92. Esther CR, Howard TE, Marino EM, Goddard JM, Capechi MR, Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996; 74: 953-965
93. McCausland JE, Bertram JF, Ryan GB, Alcorn D. Glomerular number and size following chronic angiotensin II blockade in the postnatal rat. Exp Nephrol 1997; 5: 201-209
94. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-657
95. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl A cad Sci USA 1996; 93: 156-160
96. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 1997; 272: 19022-19026
97. Ardaillou R. Angiotensin II type II receptor. Does it have a role in the normal or diseased kidney? Nephrol Dial Transplant 1994; 9: 1364-1365
98. El Nahas AM. Glomerulosclerosis: insights into the pathogenesis and treatment. Nephrol Dial Transplant 1989; 4: 843-853
99. Kuncio GS, Neilson EG, Haverty T. Mechanisms of tubulointerstitial fibrosis. Kidney Int 1991; 39: 550-556
100. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 1994; 35: F829-F842
101. Kashgarian M, Sterzel RB. The pathobiology of the mesangium. Kidney Int 1992; 41: 524-529
102. Floege J, Burns MW, Alpers CE et al. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int 1992; 41: 297-309
103. Wolf G, Neilson EG. Cellular biology of tubulointerstitial growth. Curr Topics Pathol 1995; 88: 69-97
104. El Nahas AM. Renal scarring: the role of angiotensin II. Nephrol Dial Transplant 1995; 10 [Suppl. 9]: 28-32
105. Wolf G, Zahner G, Schroeder R, Stahl RAK. Transforming growth factor beta mediates the angiotensin II-induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells. Nephrol Dial Transplant 1996; 11: 263-269
106. Kaneto H, Morrossey J, Klahr S. Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993; 44: 313-321
107. Pimentel JL, Sundell CL, Wang S, Kopp JB, Montero A, Martinez-Maldonado M. Role of angiotensin II in the expression and regulation of transforming growth factor-β in obstructive nephropathy. Kidney Int 1995; 48: 1233-1246
108. Ishidoya S, Morrissey J, McCracken R, Klahr S. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int 1996; 49: 1110-1119
109. Wolf G, Thaiss F, Stahl RAK. Cyclosporine stimulates expression of transforming growth factor-β in renal cells. Transplantation 1995; 60: 237-241
110. Wolf G, Zahner G, Ziyadeh FN, Stahl RAK. Cyclosporin A induces transcription of transforming growth factor beta in a cultured murine proximal tubular cell line. Exp Nephrol 1996; 4: 304-308
111. Wolf G, Killen PD, Neilson EG. Cyclosporin A stimulates transcription and procollagen secretion in tubulointerstitial fibroblasts and proximal tubular cells. J Am Soc Nephrol 1990; 1: 918-922
112. Shehata M, Cope GH, Johnson TS, Raftery AT, El Nahas AM. Cyclosporine enhances the expression of TGF-β in the juxtaglomerular cells of the rat kidney. Kidney Int 1995; 48: 1487-1496
113. Burdmann EA, Andoh TF, Nast CC et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am J Physiol 1995; 269: F491-F499
114. Kon V, Hunley TE, Fogo A. Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Transplantation 1995; 60: 89-95
115. Inserra F, Romano LA, de Cavanagh EMV, Ercole L, Ferder LF, Gomez RA. Renal interstitial sclerosis in aging: effects of enalapril and nifedipine. J Am Soc Nephrol 1996; 7: 676-680
116. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437
117. Nahmann NS, Rothe KL, Falkenhain ME et al. Angiotensin II induction of fibronectin biosynthesis in cultured human mesangial cells: association with CREB transcription factor activation. J Lab Clin Med 1996; 1 27: 599-611
118. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE. Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997; 51: 1553-1567
119. Lee SK, Jin SY, Han DC, Hwang SD, Lee HB. Effects of delayed treatment with enalapril and/or lovastatin on the progression of glomerulosclerosis in 5/6 nephrectomized rats. Nephrol Dial Transplant 1993; 8: 1338-1343
120. Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest 1995; 96: 953-964
121. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997; 51: 664-671
122. Feener EP, Xia P, Inoguchi T, Shiba T, Kunisaki M, King GL. Role of protein kinase C in glucose- and angiotensin II-induced plasminogen activator inhibitor expression. Contrib Nephrol 1996; 118: 180-187
123. Nguyen G, Delarue F, Berrou J, Rondeau E, Sraer JD. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996; 50: 1897-1903
124. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51: 164-172
125. Arai M, Isaka Y, Akagi Y et al. In vivo transfection of genes for renin and angiotensinogen into the glomerular cells induced phenotypic change of the mesangial cells and glomerular sclerosis. Biochem Biophys Res Commun 1995; 206: 525-532
126. Van Goor H, Ding G, Kees-Folts D, Grond J, Schreiner GF, Diamond JR. Macrophages and renal disease. Lab Invest 1994; 71: 456-464
127. Diamond JR, Anderson S. Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 1990; 137: 1323-1332
128. Eng E, Veniant M, Floege J et al. Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension. Am J Hypertens 1994; 7: 177-185
129. Mai M, Geiger H, Hilgers KF et al. Early interstitial changes in hypertension-induced renal injury. Hypertension 1993; 22: 754-765
130. Geiger H, Fierlbeck W, Mai M et al. Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR. Kidney Int 1997; 51: 750-761
131. Goetzl EJ, Klickstein LB, Watt KWK, Wintroub BU. The preferential human mononuclear leukocyte chemotactic activity of the substituent tetrapeptides of angiotensin II. Biochem Biophys Res Commun 1980; 97: 1097-1102
132. Weinstock JV, Kassab JT. Angiotensin II stimulation of granuloma macrophage phagocytosis and actin polymerization in murine schistosomiasis mansoni. Cell Immunol 1984; 89: 46-54
133. Farber HW, Center DM, Rounds S, Danilov. Components of the angiotensin system cause release of a neutrophil chemoattractant from cultured bovine and human endothelial cells. Eur Heart J 1990; 11 [Suppl. B]: 100-107
134. Ai Kim J, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun 1996; 226: 862-868
135. Wolf G, Ziyadeh FN, Thaiss F et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 1997; 100: 1047-1058
136. Ruiz-Ortega M, Bustos C, Egido J. Angiotensin II triggers monocyte chemoattractant protein-1 (MC P-1), transforming growth factor (TGF-β1) and matrix protein gene expression in mesangial cells and interstitial renal fibroblasts (abstract). Nephrol Dial Transplant 1996; 11: A58
137. Kim YS, Bhandari B, Abboud HE. Angiotensin II (ANG II) stimulates monocyte chemoattractant protein-1 (MCP-1) expression in rat mesangial cells (abstract). J Am Soc Nephrol 1996; 7: 1737
138. Satriano JA, Shuldiner M, Hora K, Xing Y, Shan Z, Schlöndorff D. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobulin G: evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J Clin Invest 1993; 92: 1564-1571
139. phox is a critical component of the superoxidegenerating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996; 271: 23317-23321
140. Wolf G, Ziyadeh FN, Schroeder R, Stahl RAK. Angiolensin II inhibits inducible nitric oxide syntahse in tubular MCT cellls by a posttranscriptional mechanism. J Am Soc Nephrol 1997; 8: 551-557
141. Matthews JR, Botting CH, Panico M, Morris HR, Hay RT. Inhibition of NF-κB DNA binding by nitric oxide. Nucl Acids Res 1996; 24: 2236-2242
142. Wolf G, Schneider A, Helmchen U, Stahl RAK. Angiotensin II-receptor antagonists abolish glomerular MCP-I expression in a model of mesangialproliferative glomerulonephritis (abstract). Nieren Hochdruckkrankh 1997; 26: 458-459
143. Scherberich JE, Wolf G, Albers C, Nowack A, Stuckhardt C, Schoeppe W. Glomerular and tubular membrane antigens reflecting cellular adaptation in human renal failure. Kidney Int 1989; 36 [Suppl. 27]: S38-S51
144. Chobanian MC, Julin CM. Angiotensin II stimulates ammoniagenesis in canine renal proximal tubule segments. Am J Physiol 1991; 260: F19-F26
145. Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic lubuloinierstitial disease in rats: interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985; 76: 667-675
146. Giachelli CM, Pichler R, Lombardi D et al. Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994; 45: 515-524
147. Iwai N, Inagami I, Ohmichi N, Kinoshita M. Renin is expressed in rat macrophagelmonocyte cells. Hypertension 1996; 27: 399-403
148. Kitazono T, Padgett RC, Armstrong ML, Tompkins PK, Heistad DD. Evidence that angiotensin II is present in human monocytes. Circulation 1995; 91: 1129-1134
149. Vance BA, Kelly CJ. A nephritogenic T cell clone expresses components of the renin-angiotensin system and is responsive to angiotensin II (abstract). J Am Soc Nephrol 1994; 5: 772A
150. Parving HH, Hommel E, Smidt EM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 1988; 297: 1086-1091
151. Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. Br Med J 1988; 297: 1092-1095
152. Bjôrck S, Mulec H, Johnson SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304: 339-343
153. The EUCLID study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792
154. Bakris GL. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med 1993; 118: 643-644
155. Romero R, Salinas I, Lucas A et al. Renal function changes in mirocalbuminuric normotensive type II diabetic patients with angiotensin-converting enzyme inhibitors. Diabetes Care 1993 16: 597-600
156. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993 329: 1456-1462
157. Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure. Am J Hypertens 1992; 5: 423-430
158. The GISEN group. Randomised placebo-controlled trial of effects of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863
159. Navis G, de Zeeuw O, de Jong PE. Commentary. ACE-inhibitors: panacea for progressive renal disease? Lancet 1997; 349: 1852-1853
160. Geiger H. Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect? Nephrol Dial Transplant 1997; 12: 640-642
161. Ichikawa I. Will angiotensin 11 receptor antagonists be renoprotective in humans ? Kidney Int 1996; 50: 684-692
162. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-1407
163. Ziai F, Ots M, Provoost AP et al. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int 1996; 50 [Suppl. 57]: S132-S136
164. Pollock DM, Divish BJ, Polakowski JS, Opgennorth TJ. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 1993; 267: 657-663
165. Remuzzi A, Perico N, Amuchastegui CS et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4: 40-49
166. Shibouta Y, Chatani F, Ishimura Y et al. TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats. Kidney Int 1996; 49 [Suppl. 55]: S115-S118
167. Fox AJ, Lalloo UG, Belvisi MG, Bernareggi M, Chung KF, Barnes PJ. Bradykinin-evoked sensitization of airway sensory nerves: a mechanism for ACE-inhibitor cough. Nature Med 1996; 2: 814-817
168. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997; 349: 747-752
169. Harris RC, Kondo S, Yasuda T. Mechanical stress-cell function relationships in renal cells. Exp Nephrol 1997; 5: 263-270